Siglec-8 as a Drugable Target to Treat Eosinophil and Mast Cell-Associated Conditions
Pharmacology and Therapeutics - United Kingdom
doi 10.1016/j.pharmthera.2012.06.005
Full Text
Open PDFAbstract
Available in full text
Categories
Date
September 1, 2012
Authors
Publisher
Elsevier BV